Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
Antares Pharma is a specialty pharmaceutical company that combines drug developmen...
Antares Pharma is a specialty pharmaceutical co...
Connector LLC is a corporation that creates highly cost-effective platforms for se...
Connector LLC is a corporation that creates hig...
We are a gene therapy company dedicated to developing and commercializing novel tr...
We are a gene therapy company dedicated to deve...
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing an...
Soligenix, Inc. is a late-stage biopharmaceutic...
KalVista is a pharmaceutical company focused on the discovery, development and com...
KalVista is a pharmaceutical company focused on...
Tenax Therapeutics is focused on developing and commercializing pharmaceutical pro...
Tenax Therapeutics is focused on developing and...
Chembio is a leading point-of-care diagnostics company focused on detecting and di...
Chembio is a leading point-of-care diagnostics ...
Join the National Investor Network and get the latest information with your interests in mind.